Next Article in Journal
Synthesis and Antimicrobial Activity of Some New Quinoxaline Derivatives
Next Article in Special Issue
Obesity Drug Update: The Lost Decade?
Previous Article in Journal
Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer's Disease and Related Disorders
Previous Article in Special Issue
Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options
Pharmaceuticals 2010, 3(8), 2398-2415; doi:10.3390/ph3082398
Review

Combinations of drugs in the Treatment of Obesity

1
,
1
,
1
,
1
,
2
,
1
 and
2,*
1 Obesity & Metabolic Syndrome Group, Discipline of Endocrinology & Metabolism, Hospital das Clínicas, Faculty of Medicine, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 255, 7º andar, sala 7037, 05403-000 - São Paulo, SP, Brazil 2 Laboratory of Carbohydrates and Radioimuneassay/LIM-18, Faculty of Medicine, University of São Paulo, Av. Dr Arnaldo, 455 01246-903 - São Paulo, SP, Brazil
* Author to whom correspondence should be addressed.
Received: 8 June 2010 / Revised: 9 July 2010 / Accepted: 15 July 2010 / Published: 27 July 2010
(This article belongs to the Special Issue Anti-Obesity Drugs)
View Full-Text   |   Download PDF [188 KB, 29 July 2010; original version 27 July 2010]

Abstract

Obesity is a chronic disease associated with excess morbidity and mortality. Clinical treatment, however, currently offers disappointing results, with very high rates of weight loss failure or weight regain cycles, and only two drugs (orlistat and sibutramine) approved for long-term use. Drugs combinations can be an option for its treatment but, although widely used in clinical practice, very few data are available in literature for its validation. Our review focuses on the rationale for their use, with advantages and disadvantages; on combinations often used, with or without studies; and on new perspectives of combinations being studied mainly by the pharmaceutical industry.
Keywords: drug combination; phentermine; fenfluramine; ephedrine; caffeine; sibutramine; orlistat; metformin; bupropion; naltrexone; zonisamide; topiramate; pramlintide; metreleptin; leptin; glucagon-like peptide-1; peptide YY; 5-hydroxytryptophan; carbidopa; noradrenergic drugs; antidepressants drug combination; phentermine; fenfluramine; ephedrine; caffeine; sibutramine; orlistat; metformin; bupropion; naltrexone; zonisamide; topiramate; pramlintide; metreleptin; leptin; glucagon-like peptide-1; peptide YY; 5-hydroxytryptophan; carbidopa; noradrenergic drugs; antidepressants
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Halpern, B.; Oliveira, E.S.L.; Faria, A.M.; Halpern, A.; Melo, M.E.; Cercato, C.; Mancini, M.C. Combinations of drugs in the Treatment of Obesity. Pharmaceuticals 2010, 3, 2398-2415.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

Cited By

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert